An accidental extravasation of anthracycline-containing chemotherapy is a feared complication that may lead to necrosis and severe tissue destruction. For four decades, much effort has been done to prevent and treat this devastating condition. Savene™ has recently been proved to be very effective, and is the only approved treatment against anthracyline extravasation. It is thus now widely recommended. The present article represents a comprehensive review of, and historical insight to, the experimental and clinical studies of surgical and non-surgical treatments of extravasation during forty years of clinical anthracycline treatment.
MouridsenH.T., LangerS.W., ButerJ., EidtmannH., RostiG., de Witt, KnoblauchP., RasmussenA., DahlstrømK., JensenP.B.: Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multi-centre studies. Ann Oncol, 18: 546–550, 2007.
KaneR.C., McGuinnW.D.J., DagherR., JusticeR., PazdurR.: Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. Oncologist, 13: 445–450, 2008.
4.
TanC., EtcubanasE., WollnerN., RosenG., GilladogaA., ShowelJ., MurphyM.L., KrakoffI.H.: Adriamycin – an antitumor antibiotic in the treatment of neoplastic diseases. Cancer, 32: 9–17, 1973.
5.
RudolphR., SteinR.S., PattilloR.A.: Skin ulcers due to adriamycin. Cancer, 38: 1087–1094, 1976.
6.
LaughlinR.A., LandeenJ.M., HabalM.B.: The management of inadvertent subcutaneous adriamycin infiltration. Am J Surg, 137: 408–412, 1979.
7.
ReillyJ.J., NeifeldJ.P., RosenbergS.A.: Clinical course and management of accidental adriamycin extravasation. Cancer, 40: 2053–2056, 1977.
8.
LarsonD.L.: Treatment of tissue extravasation by antitumor agents. Cancer, 49: 1796–1799, 1982.
9.
LarsonD.L.: What is the appropriate management of tissue extravasation by antitumor agents?Plastic Reconstr Surg75: 397–402, 1985.
BroadbentN.R., BrownG.E.: Adriamycin and soft tissue injury. N Z Med J, 98: 71, 1985.
15.
PreussP., PartoftS.: Cytostatic extravasations. Ann Plast Surg, 19: 323–329, 1987.
16.
LothT.S., EversmannW.W.J.: Extravasation injuries in the upper extremity. Clin Orthop Relat Res, 272: 248–254, 1991.
17.
PitkänenJ., Asko-SeljavaaraS., GröhnP., SundellB., HeinonenE., AppelqvistP.: Adriamycin extravasation: surgical treatment and possible prevention of skin and soft-tissue injuries. J Surg Oncol, 23: 259–262, 1983.
18.
HeitmannC., DurmusC., IngianniG.: Surgical management after doxorubicin and epirubicin extravasation. J Hand Surg [Br], 23: 666–668, 1998
19.
LangsteinH.N., DumanH., SeeligD., ButlerC.E., EvansG.R.D.: Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg, 49: 369–374, 2002.
20.
DahlstrømK.K., ChenoufiH.L., DaugaardS.: Fluorescence microscopic demonstration and demarcation of doxorubicin extravasation. Experimental and clinical studies. Cancer, 65: 1722–1726, 1990.
21.
AnderssonA.P., DahlstrømK.K.: Clinical results after doxorubicin extravasation treated with excision guided by fluorescence microscopy. Eur J Cancer, 29A: 1712–1714, 1993.
22.
RudolphR., SuzukiM., LuceJ.K.: Experimental skin necrosis produced by adriamycin. Cancer Treat Rep, 63: 529–537, 1979.
23.
DorrR.T., AlbertsD.S., ChenH.S.: Experimental model of doxorubicin extravasation in the mouse. J Pharmacol Methods, 4: 237–250, 1980.
24.
IgnoffoR.J., FriedmanM.A.: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev, 7: 17–27, 1980.
25.
SobleM.J., DorrR.T., PleziaP., BreckenridgeS.: Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics. Cancer Chemother Pharmacol, 20: 33–36, 1987.
26.
LothT.S., EversmannW.W.J.: Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg [Am], 11: 388–396, 1986.
27.
LinderR.M., UptonJ.: Prevention of extravasation injuries secondary to doxorubicin. Postgrad Med, 77: 105–109, 112, 114, 1985.
28.
ShenaqS.M., AbbaseE.H., FriedmanJ.D.: Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Surg Oncol Clin N Am, 5: 825–845, 1996.
29.
LinderR.M., UptonJ., OsteenR.: Management of extensive doxorubicin hydrochloride extravasation injuries. J Hand Surg [Am], 8: 32–38, 1983.
30.
CohenF.J., ManganaroJ., BezozoR.C.: Identification of involved tissue during surgical treatment of doxorubicin-induced extravasation necrosis. J Hand Surg [Am], 8: 43–45, 1983.
31.
BleicherJ.N., HaynesW., MassopDW, DaneffR.M.: The delineation of adriamycin extravasation using fluorescence microscopy. Plast Reconstr Surg, 74: 114–116, 1984
32.
DurayP.H., CuonoC.B., MadriJ.A.: Demonstration of cutaneous doxorubicin extravasation by rhodamine-filtered fluorescence microscopy. J Surg Oncol, 31: 21–25, 1986
33.
DorrR.T., AlbertsD.S., StoneA.: Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep, 69: 431–437, 1985.
34.
HarwoodK.V., BachurN.: Evaluation of dimethyl sulfoxide and local cooling as antidotes for doxorubicin extravasation in a pig model. Oncol Nurs Forum, 14: 39–44, 1987.
35.
LangerS.W., SehestedM., JensenP.B.: Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol, 12: 405–410, 2001.
36.
BarlockA.L., HowserD.M., HubbardS.M.: Nursing management of adriamycin extravasation. Am J Nurs, 79: 94–96, 1979.
37.
HarwoodK., GoninR.: Long term vs long term cooling after doxorubicin (DOX) extravasation: An Eastern Cooperative Oncology Group (ECOG) study. Proceed Am Soc Clin Oncol, 13: 447, 1994.
LambertF., CouturaudB., ArnaudE., ChampeauF., RevolM., ServantJ.M.: Iatrogenic extravasations of cytotoxic or hyperosmolar aqueous solutions. Value of surgical emergency by aspiration and lavage. Ann Chir Plast Esthet, 42: 305–313, 1997.
ColemanJJ3, WalkerA.P., DidolkarM.S.: Treatment of adriamycin-induced skin ulcers: a prospective controlled study. J Surg Oncol, 22: 129–135, 1983.
46.
AverbuchS.D., BoldtM., GaudianoG., SternJ.B., KochT.H., BachurN.R.: Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound. J Clin Invest, 81: 142–148, 1988.
47.
CohenM.H.: Amelioration of adriamycin skin necrosis: an experimental study. Cancer Treat Rep, 63: 1003–1004, 1979.
48.
LangerS.W., ThougaardA.V., SehestedM., JensenP.B.: Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol, 57: 125–128, 2006.
49.
PetroJ.A., GrahamWP3, MillerS.H., OverholtT., FallonT.: Experimental and clinical studies of ulcers induced with adriamycin. Surg Forum, 30: 535–537, 1979.
TsavarisN.B., KaragiaourisP., TzannouI., KomitsopoulouP., BacoyiannisC., KarabellisA., PapanicolaouV., MylonakisN., KarvounisN., ZoannouA.: Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg Oncol, 16: 519–522, 1990.
52.
TsavarisN.B., KomitsopoulouP., KaragiaourisP., LoukatouP., TzannouI., MylonakisN., KosmidisP.: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol, 30: 330–333, 1992.
53.
Bartkowski-DoddsL., DanielsJ.R.: Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats. Cancer Chemother Pharmacol, 4: 179–181, 1980.
54.
KappelB., HindenburgA.A., TaubR.N.: Treatment of anthracycline extravasation – a warning against the use of sodium bicarbonate. J Clin Oncol, 5: 825–826, 1987.
55.
SvingenB.A., PowisG., AppelP.L., ScottM.: Protection by alpha-tocopherol and dimethylsulfoxide (DMSO) against adriamycin-induced skin ulcers in the rat. Res Commun Chem Pathol Pharmacol, 32: 189–192, 1981.
56.
DorrR.T., AlbertsD.S.: Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. Cancer Treat Rep, 67: 499–501, 1983.
57.
OkanoT., OhnumaT., EfremidisA., HollandJ.F.: Doxorubicin-induced skin ulcer in the piglet. Cancer Treat Rep, 67: 1075–1078, 1983.
58.
DesaiM.H., TeresD.: Prevention of doxorubicin-induced skin ulcers in the rat and pig with dimethyl sulfoxide (DMSO). Cancer Treat Rep, 66: 1371–1374, 1982.
LudwigC.U., StollH.R., ObristR., ObrechtJ.P.: Prevention of cytotoxic drug-induced skin ulcers with dimethyl sulfoxide (DMSO) and alpha-tocopherole. Eur J Cancer Clin Oncol, 23: 327–329, 1987.
61.
OlverI.N., SchwarzM.A.: Use of dimethyl sulfoxide in limiting tissue damage caused by extravasation of doxorubicin. Cancer Treat Rep, 67: 407–408, 1983.
62.
OlverI.N., AisnerJ., HamentA., BuchananL., BishopJ.F., KaplanR.S.: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol, 6: 1732–1735, 1988.
63.
LawrenceH.J., GoodnightS.H.J.: Dimethyl sulfoxide and extravasation of anthracycline agents. Ann Intern Med, 98: 1025, 1983.
64.
LawrenceH.J., WalshD., ZapotowskiK.A., DenhamA., GoodnightS.H., GandaraD.R.: Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol, 23: 316–318, 1989.
65.
BertelliG., DiniD., FornoG., GozzaA., VenturiniM., BallellaG., RossoR.: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet, 341: 1098–1099, 1993.
66.
BertelliG., GozzaA., FornoG.B., VidiliM.G., SilvestroS., VenturiniM., Del MastroL., GarroneO., RossoR., DiniD.: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol, 13: 2851–2855, 1995.
67.
BonnetblancJ.M., BordessouleD., FayolJ., AmiciJ.M.: Treatment of accidental extravasation of antitumor agents with dimethylsulfoxide and alpha-tocopherol. Ann Dermatol Venereol, 123: 640–643, 1996.
68.
SchrijversD.L.: Extravasation: a dreaded complication of chemotherapy. Ann Oncol, 14 Suppl 3: iii26–30, 2003.
69.
AlleyE., GreenR., SchuchterL.: Cutaneous toxicities of cancer therapy. Curr Opin Oncol, 14: 212–216, 2002.
70.
DisaJ.J., ChangR.R., MucciS.J., GoldbergN.H.: Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg, 101: 370–374, 1998.
71.
HecklerF.R.: Current thoughts on extravasation injuries. Clin Plast Surg, 16: 557–563, 1989
72.
LuceroM.J., VigoJ., RabascoA.M., SanchezJ.A., MartinF.: Protection by alpha-tocopherol against skin necrosis induced by doxorubicin hydrochloride. Pharmazie, 48: 772–775, 1993.
73.
BekerecioğluM., KutluhanA., DemirtaşI., KaraayvazM.: Prevention of adriamycin-induced skin necrosis with various free radical scavengers. J Surg Res, 75: 61–65, 1998.
74.
VasilevS.A., MorrowC., MorrowC.P.: Basic fibroblast growth factor in retardation of doxorubicin extravasation injury. Gynecol Oncol, 44: 178–181, 1992.
75.
ErogluE., SariA., AltuntasI., DelibasN., CandirC., AgalarF.: The effect of GM-CSF (granulocyte macrophage colony stimulating factor) on doxorubicin-induced tissue necrosis and wound healing. Indian J Cancer, 37: 153–157, 2000.
76.
VargelI., ErdemA., ErtoyD., PinarA., ErkY., AltundagM.K., GulluI.: Effects of growth factors on doxorubicin-induced skin necrosis: documentation of histomorphological alterations and early treatment by GM-CSF and G-CSF. Ann Plast Surg, 49: 646–653, 2002.
77.
ShamseddineA.I., KhalilA.M., KibbiA.G., Abu NasrT.A., SeoudM.A., El SaghirN.S.: Granulocyte macrophage-colony stimulating factor for treatment of chemotherapy extravasation. Eur J Gynaecol Oncol, 19: 479–481, 1998.
78.
UlutinH.C., GüdenM., DedeM., PakY.: Comparison of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in the treatment of chemotherapy extravasation ulcers. Eur J Gynaecol Oncol, 21: 613–615, 2000.
79.
LangerS.W., SehestedM., JensenP.B.: Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res, 6: 3680–3686, 2000.
BosA.M., van der GraafW.T., WillemseP.H.: A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta Oncol, 40: 541–542, 2001.
82.
JensenJ.N., Lock-AndersenJ., LangerS.W., MejerJ.: Dexrazoxane – a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Surg Hand Surg, 37: 174–175, 2003.
83.
El-SaghirN., OtrockZ., MufarrijA., Abou-MouradY., SalemZ., ShamseddineA., AbbasJ.: Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol, 5: 320–321, 2004.
